Screener
Kymera Therapeutics KYMR Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Kymera Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333849
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Operating lease liabilities | 12,119 | 11,941 |
| Finance lease liabilities | 1,577 | 1,815 |
| Other current liabilities | 236 | 242 |
| Total current liabilities | $71,326 | $83,212 |
| Non-current liabilities | ||
| Deferred revenue, net of current portion | — | 11,440 |
| Operating lease liabilities, net of current portion | 64,022 | 67,034 |
| Finance lease liabilities, net of current portion | 840 | 1,462 |
Item 1. Financial Statements.
FAQ
- What is Kymera Therapeutics's total current liabilities?
- Kymera Therapeutics (KYMR) reported total current liabilities of $71.33M in Q2 2026.
- How has Kymera Therapeutics's total current liabilities changed year-over-year?
- Kymera Therapeutics's total current liabilities decreased by 18.5% year-over-year, from $87.54M to $71.33M.
- What is the long-term trend for Kymera Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), Kymera Therapeutics's total current liabilities has grown at a -5.5% compound annual growth rate (CAGR), from $110.62M to $83.21M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about Kymera Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude